Pyrimidine nucleoside analogues and antitumour drugs based on them: fifty years in therapy
- 1 February 2026
- journal article
- Published by Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii in Russian Chemical Reviews
- Vol. 95 (2) , RCR5197
Abstract
Most of the modern chemotherapeutic arsenal for the treatment of various types of cancer is based on pyrimidine nucleoside analogues. These include drugs that have been proven for decades (cytarabine, floxuridine, gemcitabine, capecitabine, azacitidine, and decitabine) as well as combinations of new antitumour agents (trifluorothymidine and tipiracil hydrochloride, decitabine and cedazuridine). New pyrimidine nucleoside analogues (doxyfluridine, tezacitabine, tiarabin, troxacitabine, etc.) and their depot forms (sapacitabine, MB-07133, etc.) are currently undergoing clinical trials for monotherapy or combination therapy for a wide range of oncological diseases. Over the past 15 years, publications have appeared describing various approaches to optimize the synthesis methods and structures of existing cancer drugs, as well as the design and synthesis of new pyrimidine nucleoside analogues with antitumour activity. This review summarizes new information and classical methods for synthesizing pyrimidine nucleoside analogues, as well as data on their antitumour activity, targets, and mechanisms of action. This review will be useful to a wide range of readers, including undergraduate and graduate students in chemistry and biology, and also specialists in chemistry, biology and medicine. The bibliography includes 216 references.Keywords
This publication has 198 references indexed in Scilit:
- A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patientsInternational Journal of Cancer, 2024
- Epigenetic Anti‐Cancer Treatment With a Stabilized Carbocyclic Decitabine AnalogueChemistry – A European Journal, 2022
- Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Cancer, 2021
- Influencing Epigenetic Information with a Hydrolytically Stable Carbocyclic 5‐Aza‐2′‐deoxycytidineAngewandte Chemie International Edition, 2019
- Phase 1/2 study of DFP‐10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemiaCancer, 2019
- Antiviral and Cytostatic Evaluation of 5‐(1‐Halo‐2‐sulfonylvinyl)‐ and 5‐(2‐Furyl)uracil NucleosidesArchiv der Pharmazie, 2017
- Phase II study of TAS‐106 in patients with platinum‐failure recurrent or metastatic head and neck cancer and nasopharyngeal cancerCancer Medicine, 2013
- Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndromeCancer, 2010
- Synthesis of 4′‐C‐Acylated ThymidinesHelvetica Chimica Acta, 1996
- Nucleotides. Part XLVIII. Synthesis of 2′‐amino‐2′‐deoxyarabinonucleoside phosphoramidite building blocksHelvetica Chimica Acta, 1996